Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2007-04-24
2007-04-24
Haddad, Maher M. (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S143100, C424S155100
Reexamination Certificate
active
10380611
ABSTRACT:
The present invention relates to methods of modulating angiogenesis and inhibiting tumor progression by using TWEAK receptor (Fn14) agonists. In particular, methods for inhibiting angiogenesis are disclosed.
REFERENCES:
patent: 4777245 (1988-10-01), Foung et al.
patent: 5073492 (1991-12-01), Chen et al.
patent: 5858991 (1999-01-01), Hellerqvist et al.
patent: 6207642 (2001-03-01), Wiley
patent: 6448042 (2002-09-01), Greene
patent: 6492123 (2002-12-01), Holliger et al.
patent: 6544761 (2003-04-01), Greene et al.
patent: 6608048 (2003-08-01), Tsou et al.
patent: 6727225 (2004-04-01), Wiley
patent: 6824773 (2004-11-01), Wiley
patent: 6943146 (2005-09-01), Jakubowski et al.
patent: 2002/0004041 (2002-01-01), Matthew et al.
patent: 2002/0042368 (2002-04-01), Fanslow et al.
patent: 2002/0110853 (2002-08-01), Wiley
patent: 2003/0100074 (2003-05-01), Yu et al.
patent: 2003/0148314 (2003-08-01), Berger et al.
patent: 2003/0162712 (2003-08-01), Cerretti et al.
patent: 2003/0170228 (2003-09-01), Ashkenazi et al.
patent: 2003/0198640 (2003-10-01), Yu et al.
patent: 2003/0211096 (2003-11-01), Ashkenazi et al.
patent: 2003/0211993 (2003-11-01), Jakubowski et al.
patent: 2003/0216546 (2003-11-01), Tykocinski
patent: 2004/0014176 (2004-01-01), Ashkenazi et al.
patent: 2004/0018170 (2004-01-01), Shirwan
patent: 2004/0033495 (2004-02-01), Murray et al.
patent: 2004/0038349 (2004-02-01), Hilbert et al.
patent: 2004/0047854 (2004-03-01), Black et al.
patent: 2004/0076955 (2004-04-01), Mack et al.
patent: 2004/0091473 (2004-05-01), DuBose et al.
patent: 2004/0175744 (2004-09-01), Hu et al.
patent: 2005/0008636 (2005-01-01), Rennert
patent: 2005/0054568 (2005-03-01), Ling et al.
patent: 2005/0112666 (2005-05-01), Browning et al.
patent: 2005/0118629 (2005-06-01), Browning et al.
patent: 2005/0181375 (2005-08-01), Aziz et al.
patent: 2005/0208500 (2005-09-01), Erlander et al.
patent: WO 96/18725 (1996-06-01), None
patent: WO 98/05783 (1998-02-01), None
patent: WO 98/35061 (1998-08-01), None
patent: WO 98/55508 (1998-12-01), None
patent: WO 99/11791 (1999-03-01), None
patent: WO 99/19490 (1999-04-01), None
patent: WO 99/59614 (1999-11-01), None
patent: WO 99/61471 (1999-12-01), None
patent: WO 00/37638 (2000-06-01), None
patent: WO 00/42073 (2000-07-01), None
patent: WO 01/45730 (2001-06-01), None
patent: WO 01/45730 (2001-06-01), None
patent: WO 01/53486 (2001-07-01), None
patent: WO 01/85193 (2001-11-01), None
patent: WO 03/86311 (2003-10-01), None
Kogan et al. A Single Amino Acid Residue Can Determine the Ligand Specificity of E-selectin J. Biol. Chem. 1995 270: 14047-14055.
Colman PM. Effects of amino acid sequence changes on antibody-antigen interactions. Res Immunol. 145(1):33-36, 1994.
Ho et al Soluble tumor necrosis factor-like weak inducer of apoptosis overexpression in HEK293 cells promotes tumor growth and angiogenesis in athymic nude mice. Cancer Res. Dec. 15, 2004;64(24):8968-72.
Ward et al., “Blocking of adhesion molecules in vivo as anti-inflammatory therapy”, Ther. Immunol., vol. 1(3), pp. 165-171 (1994).
Ngo et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox”, The Protein Folding Problem, Chapter 14, pp. 435-508 (1994).
Dallman, “Cytokines and transplantation: Th1/Th2 regulation of the immune response to solid organ transplants in the adult”, Current Opinion in Immunology, vol. 7, pp. 632-638 (1995).
Krenger and Farrara, “Graft-versus-Host Disease and the Th1/Th2 Paradigm”, Immunol. Res., vol. 15, pp. 50-73 (1996).
Toogood et al., “The Immune Response Following Small Bowel Transplantation”, Transplantation, vol. 62(6), pp. 851-855 (1996).
De Wit et al., “Preferential Activation of Th2 Cells in Chronic Graft-versus-Host Reaction”, The Journal of Immunology , col. 150 (2), pp. 361-366 (1993).
Williamson et al., “IL-12 Is a Central Mediator of Acute Graft-Versus-Host Disease in Mice”, J. Immunol., pp. 689-699 (1996).
Nagata, “Apoptosis by Death Factor” Cell 88:355-365, (1997).
Chicheportiche et al., “Down-regulated expression of TWEAK mRNA in acute and chronic inflammatory Pathologies,” Biochem Biophys Res Commun., Dec. 9;279(1):162-5 (2000).
Chicheportiche et al., “Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies”, Arthritis Res. 2002, 4(2):126-33, Epub Nov. 9, 2001.
Jakubowksi,, “TWEAK Synergizes with Basis Fibroblast Growth Factor to Induce Endothelial Cell Proliferation, Migration and Lumen Morphogenesis”, Scand. J. Immunol., 51:Sup. 1:62 (2000).
Jakubowski, “Dual Role for TWEAK in angiogenic regulation” J. Cell Science, 115:267-274 (2002).
Abbas AK et al. (eds), Chapter Fifteen, “Immunity to Microbes”,Cellular and Molecular Immunology, Philadelphia: WB Saunders Co. pp. 302-314 (1991).
Abbas AK et al. (eds), Chapter One, “General Properties of Immune Responses”, Introduction to Immunology,Cellular and Molecular Immunology, Philadelphia: WB Saunders Co. pp. 4-12 (1991).
Chaplin and Fu, “Cytokine regulation of secondary lymphoid organ development”, Current Opinion in Immunology, vol. 10, pp. 288-297 (1998).
Grewal and Flavell, “The CD40 Ligand”, Immunol. Res., vol. 16, pp. 59-70 (1997).
Mackay and Browning, “Turning off follicular dendritic cells”, Nature, vol. 395, pp. 26-27 (1998).
Flynn et al., “CD4 T Cell Cytokine Differentiation: The B Cell Activation Molecule, OX40 Ligand, Instructs CD4 T Cells to Express Interleukin 4 and Upregulates Expression of the Chemokine Receptor, Blr-1”, J. Exp. Med., vol. 188, pp. 297-304 (1998).
Lynch et al., “Tweak Induces Proliferation in Endothelial Cells and Substitutes For EGF and Hydrocortisone in Culture”, Interferon Cytokine Res., vol. 18, A-46 (1998).
Marsters et al., “Identification of a ligand for the death-domain-containing receptor Apo3”, Current Biology, vol. 8, pp. 525-528 (1998).
Ashkenazi and Dixit, “Death Receptors: Signaling and Modulation”, Science, vol. 281, pp. 1305-1308 (1998).
Lenschow et al., “Differential Effects of Anti-B7-1 and Anti-B7-2 Monoclonal Antibody Treatment on the Development of Diabetes in the Nonobese Diabetic Mouse”, J. Exp. Med., vol. 181, pp. 1145-1155 (1995).
Durie et al., “Antibody to the Ligand of CD40, gp39, Blocks the Occurrence of the Acute and Chronic Forms of Graft-vs-Host Disease”, J. Clin. Invest., vol. 94, pp. 1333-1338 (1994).
Grewal and Flavell, “The Role of CD40 Ligand in Costimulation and T-Cell Activation”, Immunol. Rev., vol. 153, pp. 85-106 (1996).
Mohan et al., “Interaction Between CD40 and Its Ligand gp39 in the Development of MurineLupus nephritis1”, J. Immunol., vol. 154, pp. 1470-1480 (1995).
Kalled et al., “Anti-CD40 Ligand Antibody Treatment of SNF1Mice with Established Nephritis: Preservations of Kidney Function”, J. Immunol., vol. 160, pp. 2158-2165 (1998).
Bach-Elias et al., “Presence of autoantibodies against small nuclear ribonucleoprotein epitopes in Chagas' patients' sera”, Parasitol. Res., vol. 84, pp. 196-799 (1998).
Tibbetts et al., “Cardiac Antigen-Specific Autoantibody Production is Associated with Cardiomyopathy inTrypansomacruzi-Infected Mice1”, J. Immunol., vol. 152, pp. 1493-1499 (1994).
Kirk et al., “CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates”, Proc. Natl. Acad. Sci. USA, vol. 94, pp. 8789-8794 (1997).
Kaplan et al., “Th2 Lymphocytes Kill Antigen Presenting Macrophages Through a TWEAK Dependant Pathway”, J. of Investigative Medicine, vol. 46:287A (1998).
Meighan-Mantha et al., “The Mitogen-inducible Fn14 Gene Encodes a Type I Transmembrane Protein that Modulates Fibroblast Adhesion and Migration” J. Biol. Chem., 274: 33166-33176 (Nov. 1999).
Cassiano et al., “Molecul
Browning Jeffrey
Burkly Linda
Jakubowski Aniela
Zheng Timothy
Biogen Idec MA Inc.
Fish & Richardson P.C.
Haddad Maher M.
LandOfFree
Tweak receptor agonists as anti-angiogenic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tweak receptor agonists as anti-angiogenic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tweak receptor agonists as anti-angiogenic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3803065